Breaking litigation finance news and analysis of interest to the full range of stakeholders, including claim holders, law firms, corporate legal departments, investors, and more. Industry trends, emerging practices, and expert insight and commentary on subjects ranging from international arbitration to access to justice.
Litigation Finance for Boutique Law Firms
Lee Drucker
Several months ago I described how litigation finance can be used by entrepreneurial litigators at large law firms to build sustainable high-end litigation practices outside the traditional route of cultivating relationships with the largest corporations and their general counsel.
Many of the same challenges that I discussed facing young partners at large law firms manifest more acutely at emerging law firms trying to sustain and grow a business as they attract new clients, build brand awareness, manage salaries, and generally maintain operations.
Read MoreIs Litigation Finance Right for Your Client?
Lee Drucker
Litigation can get expensive, fast. Litigation finance is a funding tool many companies are considering to help cover the fees and expenses related to major legal claims. We at Lake Whillans Litigation Finance have compiled a list of questions to help you determine if your client is a candidate for litigation finance. Is litigation finance…
Read MoreLitigation Finance: 10 Questions to Help Advise Your Client
Lee Drucker
We, at Lake Whillans, have been writing a lot about litigation finance in order to provide lawyers and claimholders with a framework for thinking about its use and potential benefits. I thought it might be time to take a break from writing, and provide an analytics tool to help claimholders and their lawyers determine whether litigation finance makes sense for the business.
Read MoreHow to Build a Quality Litigation Finance Firm
Lee Drucker
It might seem pretty obvious that picking smart investments is critical for developing a successful litigation funding company, but what might not be obvious are all of the reasons why.
Read MoreChanging Landscape of Medtech Innovation
Lee Drucker
Last week in Medcity News, Tiffany Wilson Karp, the executive director of the Global Center for Medical Innovation, discussed the changing landscape for early stage funding in the medical device space, including that “[v]enture capital is essentially out of the early-stage medtech investing business” and that she is “seeing an increased interest from corporate venture capital (large medical device companies, for example) which face gaps in their innovation pipelines in the future and may be open to creative ways to engage with early-stage companies who are working on problems they want to address or product pipelines they want to fill.”
Read MoreLife Science Entrepreneurs Facing Litigation
Lee Drucker
Developing a new product or business in the healthcare space is rife with complexity. Whether it be creating a new medical device, an innovative pharmaceutical, or a digital health business, healthcare entrepreneurs must identify a valuable opportunity, assemble a dedicated and talented team, potentially invest years and abundant resources in R&D – all of which may occur before seeking FDA approval, finding manufacturing partners, or even knowing whether you have a viable product for the market. Given these challenges, the last thing on a CEO’s mind when raising capital or finding partners to navigate these complexities may be how to defend the company if one of these partnerships goes sideways. But what happens if one of these partnerships does go awry? If a partner, having learned the secrets of a company’s technology determines to take that knowledge for itself? (Last week, F. Nicholas Franano, MD, a radiologist and chief executive officer at two cardiovascular medical device companies, Flow Forward Medical and Metactive Medical discussed how companies can best protect themselves when entering these partnerships.) Or if a competitor takes action to derail the company? (here is an in-depth article about a company in that position). Is all of the work of the talented and dedicated people that helped drive the initial success of the company lost?
Read MoreLake Whillans Investment Featured in MEDCITY News
Lee Drucker
An in depth article about a fabulous entrepreneur and promising cancer therapy almost derailed by impropriety. This was one of Lake Whillans’ first investments:
http://medcitynews.com/2015/03/entrepreneur-nearly-lost-company-heres-litigation-finance-helped-fight-back/
Read MoreLitigation Finance & Private Equity
Lee Drucker
About a month ago, I discussed the venture capital landscape, and why litigation funders are attractive partners for VCs and VC-backed companies in need of resources to adequately defend their businesses. A similar, but distinct, phenomenon exists in private equity.
Private equity firms (which invest in a broader class of companies and employ a wider array of value generating techniques than venture capital) share some common characteristics that make litigation finance a useful product within the industry.
Read MoreCost of Capital in Litigation Funding
Lee Drucker
At Lake Whillans, I spend most of my time valuing litigation related assets. There are many considerations in this exercise, some of which I wrote about here.
Today, I am going to write about cost of capital, which is a key component in valuation. Aswath Damodaran recently wrote:
“If there were a contest for the most measured number in finance, the winner would be the cost of capital. Corporate finance departments around the world compute it as an integral part of investment analysis. Appraisers estimate it as a step towards estimating intrinsic or discounted cash flow value. Analysts spend disproportionate amounts of their time working on it, though not always for the right reasons or with the right inputs.”
Venture Capital & Litigation Finance
Lee Drucker
Venture capitalists invest in early stage growth companies, typically in high technology industries, such as biotechnology, energy, or IT. While many of these investments go on to become Tesla, Amazon, or the next life-saving pharmaceutical, about 65% of venture financings return 0-1x. Many of these investments fail simply by virtue of the high-risk nature of…
Read More